Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15226732 | 0.86 | CNR2 (0.42) | POLBCTSSCTSKCNR2MAPK1 | |
| SCHEMBL1115253 | 0.86 | LMNA (0.48) | POLBLMNACTSSCTSKCNR2 | |
| SCHEMBL10129489 | 0.84 | CTSS (0.43) | CTSSCTSKSCN9ARENCTSL | |
| SCHEMBL1115222 | 0.82 | LMNA (0.49) | POLBLMNACTSSCTSKCNR2 | |
| SCHEMBL807933 | 0.80 | CTSS (0.39) | LMNACTSSCTSKCTSLAVPR2 | |
| SCHEMBL10130112 | 0.80 | CTSS (0.49) | POLBLMNACTSSCTSKCNR2 | |
| SCHEMBL807758 | 0.79 | CNR2 (0.41) | POLBLMNACTSSCTSKCNR2 | |
| SCHEMBL10129819 | 0.79 | CTSS (0.46) | POLBCTSSCTSKGABRB1GABRB2 | |
| Hydrochloric Acid SCHEMBL15226476 | 0.78 | CNR2 (0.40) | POLBLMNACTSSCTSKCNR2 | |
| SCHEMBL807378 | 0.78 | CTSS (0.47) | POLBLMNACTSSCTSKCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616448-B1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-9034855-B2 | Substituted phenylacetate and phenylpropane amides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034855-B2 | Substituted phenylacetate and phenylpropane amides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| WO-2012035075-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | AADAC, NAT1, DNPEP | POLB 2129/4885LMNA 523/4885CTSS 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.